Table II.

Proportions of T cell subsets in two groups with MDR-TB over the course of treatment (x ± SD)

	Study point	n	CD3+ (%)	CD4+ (%)	CD8+ (%)	CD4+/CD8+
Control	0 month	24	62.67 ±14.58	34.64 ±11.05	24.26 ±11.00	1.73 ±0.92
	1 month	21	61.55 ±13.94	33.32 ±9.70	25.99 ±12.70	1.52 ±0.58
	3 month	22	62.74 ±13.77	34.15 ±11.89	25.00 ±10.11	1.43 ±0.67
	7 month	21	63.07 ±14.16	35.22 ±11.33	24.58 ±9.83	1.61 ±0.76
rhIL-2	0 month	22	59.85 ±16.09	35.41 ±9.99	23.48 ±7.20	1.66 ±0.77
	1 month	21	63.93 ±11.15	36.13 ±8.66	24.47 ±7.72	1.63 ±0.70
	3 month	22	57.04 ±15.94	31.01 ±9.90	24.63 ±8.42	1.47 ±0.87
	7 month	22	58.82 ±12.29	31.58 ±9.28	24.27 ±7.49	1.41 ±0.61

Data are expressed as mean ± standard deviation. The proportions of CD3⁺, CD4⁺, CD8⁺, and CD4⁺/CD8⁺ are assessed in different numbers of patients prior to the study and during TB treatment. MDR-TB – multidrug-resistant tuberculosis. rhIL-2 – recombinant human interleukin-2.